Cytosorbents Corp (CTSO) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Cytosorbents Corporation is a medical device company focused on blood purification technology, primarily through its flagship product, CytoSorb, which is approved in the EU for treating cytokine storms and other critical conditions. The company is currently pursuing FDA marketing approval for its DrugSorb-ATR system following the completion of the pivotal STAR-T clinical trial.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | Q2 2023 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|---|
| Total Revenue | $9.89 million | $9.42 million | $19.68 million | $18.87 million |
| Product Sales | $8.84 million | $8.07 million | $17.83 million | $15.98 million |
| Grant Income | $1.05 million | $1.35 million | $1.85 million | $2.89 million |
| Gross Profit | $6.50 million | $6.02 million | $13.07 million | $11.47 million |
| Gross Margin | 65.7% | 63.9% | 66.4% | 60.8% |
| Net Loss | $(4.14) million | $(6.15) million | $(10.50) million | $(13.48) million |
| Cash & Equivalents | $8.46 million (Unrestricted) as of June 30, 2024 | |||
| Restricted Cash | $6.48 million as of June 30, 2024 | |||
| Long-Term Debt | $13.67 million (Net of discounts) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 5% quarter-over-quarter (QoQ) and 4% year-over-year (YoY). Product sales grew 10% QoQ, driven by a 28% increase in distributor sales, partially offset by a 4% decrease in direct sales.
- Expense Reduction: Research and Development (R&D) expenses decreased significantly by 59% QoQ ($1.52M vs $3.67M) due to the completion of the STAR-T clinical trial in late 2023. Selling, General, and Administrative (SG&A) expenses remained relatively flat, decreasing slightly by 2% QoQ.
- Foreign Currency Impact: The company recorded a loss of $544,000 on foreign currency transactions in Q2 2024, compared to a gain of $415,000 in Q2 2023, due to the weakening of the Euro against the U.S. dollar.
- Debt Financing: In June 2024, the company secured a $20 million term-loan facility with Avenue Capital Group. The first tranche of $15 million was funded, with $10 million immediately available and $5 million restricted pending milestones. This facility was used to pay off existing debt with Bridge Bank.
Guidance, Outlook, and Risks
- Regulatory Outlook: Management expects to submit regulatory applications for DrugSorb-ATR to the FDA and Health Canada in the third quarter of 2024, based on STAR-T trial data which met the primary safety endpoint and showed reduced bleeding in the isolated CABG population.
- Liquidity and Going Concern: The filing includes a "substantial doubt" disclosure regarding the company's ability to continue as a going concern. Unrestricted cash ($8.46 million) is not expected to fund operations beyond the next 12 months without additional capital. The company is pursuing milestones to release restricted cash and evaluating other financing options.
- Strategic Initiatives: The company launched its PuriFi hemoperfusion machine in the EU in June 2024 to simplify treatment delivery. It continues to expand direct sales territories in the UK, Ireland, and France.
- Risks: Key risks include the failure to achieve FDA approval for DrugSorb-ATR, the inability to raise additional capital, and continued volatility in foreign exchange rates impacting financial results.
Investor Verification Checklist
- Cash Runway: Verify the timeline for releasing the $5 million in restricted cash from the Avenue facility and the status of equity fundraising efforts.
- Regulatory Submission: Confirm the filing date of the DrugSorb-ATR De Novo 510(k) application with the FDA in Q3 2024.
- Debt Covenants: Review the specific milestones required to access the remaining $5 million tranche of the Avenue loan and the interest rate structure (Prime + 5% or 13.5%).
- Revenue Concentration: Note that a significant portion of revenue comes from Germany and a small number of distributors; monitor for any concentration risks.
- Going Concern Status: Assess the company's ability to meet its obligations without further dilutive equity offerings or additional debt.